论文部分内容阅读
目的探讨美罗华联合化疗治疗B细胞非霍奇金淋巴瘤的临床疗效及安全性。方法 2011年12月~2012年12月本院收治的B细胞非霍奇金淋巴瘤患者36例,进行美罗华联合化疗治疗,三个周期后进行临床疗效及安全性的评价。结果 36例患者中完全缓解(CR)27例(75.0%),部分缓解(PR)8例(22.2%);总有效率(OR)为97.2%。治疗后随访12个月,32例存活8个月以上(88.8%),24例存活12个月以上(80.5%)。主要的不良反应为化疗相关的血液学毒性反应及发热、皮疹、哮喘、低免疫球蛋白血症等美罗华输注相关毒副反应,对症治疗后均得到缓解。结论美罗华联合化疗治疗B细胞非霍奇金淋巴瘤高效、安全,可作为优先选择疗法。
Objective To investigate the clinical efficacy and safety of rituximab in combination with chemotherapy for B cell non-Hodgkin’s lymphoma. Methods Thirty-six patients with B-cell non-Hodgkin’s lymphoma admitted to our hospital from December 2011 to December 2012 were treated with rituximab combined with chemotherapy. The clinical efficacy and safety were evaluated after three cycles. Results Among the 36 patients, 27 (75.0%) had complete remission (CR) and 8 (22.2%) had partial remission (PR). The total effective rate (OR) was 97.2%. After treatment for 12 months, 32 patients survived for more than 8 months (88.8%) and 24 patients survived for 12 months (80.5%). The main adverse reactions were chemotherapeutic-related hematological toxicity and fever-related reactions such as fever, rash, asthma, and low immunoglobulinuria, which were all relieved after symptomatic treatment. Conclusion Rituximab in combination with chemotherapy for the treatment of B-cell non-Hodgkin’s lymphoma is highly effective and safe and can be used as the preferred therapy.